XML 84 R52.htm IDEA: XBRL DOCUMENT v3.6.0.2
Fair Value Measurement (Tables)
12 Months Ended
Dec. 31, 2016
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
As of December 31, 2016 and December 31, 2015, the following financial assets and liabilities are measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3).
 
(In millions)
Carrying value and fair value
As of December 31, 2016
Total
 
Level 1
 
Level 2
 
Level 3
Financial assets:
 

 
 

 
 

 
 

Marketable equity securities
$
65.8

 
$
65.8

 
$

 
$

Marketable debt securities
15.5

 
3.6

 
11.9

 

Contingent consideration receivable
15.6

 

 

 
15.6

Derivative contracts
18.0

 

 
18.0

 

Total
114.9

 
69.4

 
29.9

 
15.6

 
 
 
 
 
 
 
 
Financial liabilities:
 

 
 

 
 

 
 

Derivative contracts
8.3

 

 
8.3

 

Contingent consideration payable
1,058.0

 

 

 
1,058.0

Total
$
1,066.3

 
$

 
$
8.3

 
$
1,058.0


(In millions)
Carrying value and fair value
As of December 31, 2015
Total
 
Level 1
 
Level 2
 
Level 3
Financial assets:
 

 
 

 
 

 
 

Marketable equity securities
$
17.2

 
$
17.2

 
$

 
$

Contingent consideration receivable
13.8

 

 

 
13.8

Derivative contracts
1.9

 

 
1.9

 

Total
32.9

 
17.2

 
1.9

 
13.8

 
 
 
 
 
 
 
 
Financial liabilities:
 

 
 

 
 

 
 

Derivative contracts
11.5

 

 
11.5

 

Contingent consideration payable
475.9

 

 

 
475.9

Total
$
487.4

 
$

 
$
11.5

 
$
475.9

Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)
The following table provides a roll forward of the fair values of our contingent consideration receivable and payables which include Level 3 measurements:
 
Contingent consideration receivable  
 
(In millions)
2016
 
2015
Balance at January 1,
$
13.8

 
$
15.9

Change in fair value included in earnings
1.6

 
13.6

Other
0.2

 
(15.7
)
Balance at December 31,
$
15.6

 
$
13.8

Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)
Contingent consideration payable  
 
 
 
(In millions)
2016
 
2015
Balance at January 1,
$
475.9

 
$
629.9

Additions
565.4

 
92.8

Change in fair value included in earnings
11.1

 
(149.9
)
Other
5.6

 
(96.9
)
Balance at December 31,
$
1,058.0

 
$
475.9

Fair Value Inputs, Assets Quantitative Information Table
Quantitative information about the Company’s recurring Level 3 fair value measurements is included below:
 
Financial assets:
Fair value at the measurement date
As of December 31, 2016
 
 
 
 
 
 
 
(In millions, except %)
Fair value
 
Valuation
technique
 
Significant unobservable inputs
 
Range
Contingent consideration receivable ("CCR")
$
15.6

 
Income approach (probability weighted discounted cash flow)
 
 Probability weightings applied to different sales scenarios
 
 
 10 to 90%
 
 
 

 
 
 
 Future forecast consideration receivable based on contractual terms with purchaser
 
 
 $0 to $21 million
 
 
 

 
 
 
 Assumed market participant discount rate
 
8%
Fair Value Measurements, Nonrecurring
The carrying amounts and estimated fair values of the Company’s financial assets and liabilities are as follows: 
 
December 31, 2016
 
December 31, 2015
(In millions)
Carrying amount
Fair value
 
Carrying amount
Fair value
Financial liabilities:
 
 
 
 
 
Senior Notes
$
12,039.2

$
11,633.8

 
$

$

Baxalta Notes
5,063.6

5,066.5

 


Capital lease obligation
353.6

353.6

 
13.4

13.4

Fair Value Inputs, Liabilities Quantitative Information Table
Financial liabilities:
Fair value at the measurement Date
As of December 31, 2016
 
 
 
 
 
 
 
(In millions, except %)
Fair value
 

 
Valuation
technique
 
Significant unobservable inputs
 
Range
Contingent consideration payable
$
1,058.0

 
Income approach (probability weighted discounted cash flow)
 
 Cumulative probability of milestones being achieved
 
 
 6 to 90%
 
 

 
 
 
 Assumed market participant discount rate
 
 
 1.2 to 10.5%
 
 
 

 
 
 
 Periods in which milestones are expected to be achieved
 
 
 2017 to 2040
 
 
 
 
 
 
 Forecast quarterly royalties payable on net sales of
relevant products
 
 
 $0.1 to $7.5 million